SIRT1 and neoplasm: Despite promising preclinical evidence, clinical trials assessing the efficacy of SIRT1 inhibitors in cancer therapy are limited, possibly due to contradictory findings regarding SIRT1’s role as an oncogene or tumor suppressor.